HC Wainwright Issues Optimistic Forecast for IOVA Earnings

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) – Equities research analysts at HC Wainwright raised their Q3 2026 earnings estimates for shares of Iovance Biotherapeutics in a note issued to investors on Tuesday, September 29th. HC Wainwright analyst J. Pantginis now expects that the biotechnology company will post earnings of ($0.09) per share for the quarter, up from their previous forecast of ($0.12). HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Iovance Biotherapeutics’ current full-year earnings is ($0.46) per share. HC Wainwright also issued estimates for Iovance Biotherapeutics’ Q4 2026 earnings at ($0.10) EPS, FY2026 earnings at ($0.49) EPS and FY2027 earnings at ($0.24) EPS.

Iovance Biotherapeutics (NASDAQ:IOVA) last announced its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.02. The business had revenue of $99.31 million for the quarter, compared to analyst estimates of $87.83 million. Iovance Biotherapeutics had a negative net margin of 89.11% and a negative return on equity of 40.51%. Iovance Biotherapeutics’s revenue was up 65.7% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.33) earnings per share.

Several other research firms have also weighed in on IOVA. Barclays increased their target price on Iovance Biotherapeutics from $13.00 to $15.00 and gave the company an “overweight” rating in a research note on Thursday, September 17th. TD Cowen upped their price target on Iovance Biotherapeutics from $7.00 to $10.00 and gave the company a “buy” rating in a research note on Monday, August 24th. Wells Fargo & Company upped their price target on Iovance Biotherapeutics from $14.00 to $18.00 and gave the company an “overweight” rating in a research note on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Iovance Biotherapeutics in a research report on Tuesday. Finally, Citizens Jmp lifted their price objective on shares of Iovance Biotherapeutics from $5.00 to $8.00 and gave the stock a “market outperform” rating in a research note on Friday, August 7th. Nine analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Iovance Biotherapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $12.40.

Iovance Biotherapeutics Stock Down 4.0%

Shares of Iovance Biotherapeutics stock opened at $14.23 on Thursday. Iovance Biotherapeutics has a 12 month low of $1.76 and a 12 month high of $15.30. The business has a fifty day simple moving average of $8.16 and a 200 day simple moving average of $5.42. The stock has a market cap of $6.45 billion, a PE ratio of -19.49 and a beta of 0.75.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in IOVA. Sequoia Financial Advisors LLC lifted its stake in Iovance Biotherapeutics by 5.4% in the second quarter. Sequoia Financial Advisors LLC now owns 32,957 shares of the biotechnology company’s stock valued at $137,000 after buying an additional 1,691 shares in the last quarter. Tidal Investments LLC boosted its holdings in shares of Iovance Biotherapeutics by 52.1% in the second quarter. Tidal Investments LLC now owns 280,048 shares of the biotechnology company’s stock valued at $1,165,000 after buying an additional 95,933 shares during the period. Engineers Gate Manager LP increased its position in shares of Iovance Biotherapeutics by 76.5% during the second quarter. Engineers Gate Manager LP now owns 190,035 shares of the biotechnology company’s stock worth $791,000 after acquiring an additional 82,338 shares in the last quarter. Integrated Wealth Concepts LLC bought a new stake in shares of Iovance Biotherapeutics during the second quarter worth $55,000. Finally, Baird Financial Group Inc. raised its holdings in shares of Iovance Biotherapeutics by 12.0% during the second quarter. Baird Financial Group Inc. now owns 222,340 shares of the biotechnology company’s stock worth $925,000 after acquiring an additional 23,800 shares during the period. 77.03% of the stock is currently owned by institutional investors.

Key Stories Impacting Iovance Biotherapeutics

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Iovance raised its 2026 revenue outlook to $410 million–$420 million, citing strong demand for its marketed therapies. The improved guidance fueled the recent surge and signals accelerating commercial adoption. IOVA Stock Hits 52-Week High on Raised Revenue Outlook for 2026
• Positive Sentiment: HC Wainwright maintained a Buy rating and a $20 price target while raising its EPS estimates: 2026 losses to $0.49 per share from $0.58, 2027 losses to $0.24 from $0.35, and improving third- and fourth-quarter loss estimates. The revisions suggest better-than-expected operating performance. HC Wainwright Brokers Increase Earnings Estimates for IOVA
• Positive Sentiment: Wells Fargo raised its price target from $14 to $18 and assigned an Overweight rating. TD Cowen also initiated or reiterated a Buy rating, reinforcing favorable Wall Street sentiment. Iovance Receives a Buy from TD Cowen
• Neutral Sentiment: Iovance appointed Noah Berkowitz, M.D., Ph.D. as chief medical officer. His global drug-development experience in T-cell therapies could support clinical development and commercialization, although the appointment does not immediately change financial results. Iovance Appoints Noah Berkowitz as Chief Medical Officer
• Negative Sentiment: After gaining roughly 31% in the prior session, IOVA is experiencing some pullback and profit-taking. The stock’s elevated valuation and continuing expected losses leave it vulnerable to volatility if revenue growth or earnings improvements fall short of expectations. Iovance Shares Surge 31.5 Percent

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc is a biotechnology company focused on developing and commercializing individualized cell therapies for patients with cancer. The company’s platform uses tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient’s tumor, expanded in a manufacturing facility and reinfused to help the immune system recognize and attack cancer cells.

Iovance’s lead product, Amtagvi (lifileucel), is an autologous TIL therapy approved by the U.S. Food and Drug Administration for certain adults with unresectable or metastatic melanoma that has progressed following prior treatment with a PD-1-blocking antibody and, when applicable, a BRAF-targeted therapy.